CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Biotechnology

Healthcare
$4.10 +2.42%

+$0.10 today

Market cap
$257.29M
Beta
0.08
P/E (TTM)
-2.8
EPS (TTM)
-$1.49
52W Low $1.31High $7.75

Volume 0.19M

Average 0.10M

CAMP Net Income

Bottom-line profit, the starting point for calculating cash from operations.

CAMP4 Therapeutics CorporationNASDAQ: CAMP

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q1 FY2026 net income of $18.33M (cash outflow) rose 47.4% year over year, behind the +66.7% change in trailing-twelve-month net income. Sequentially, it fell 54.5% from the prior quarter.

Context

  • Net income amounted to 2298.5% of revenue in FY2025, down 5644.9 pp from a year earlier.
  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 7 analysts of -$34.41M (-57.2%) for the fiscal year ending Dec 2026, a slowdown from the +55.2% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$18.33M-54.5% QoQ
Last fiscal yearDec 2025
-$80.4M+55.2% YoY
LTMMar 2026
-$86.3M+66.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+47.4%+32.6%-14.8 pp
1 year+55.2%-57.2%-112.5 pp
3-year CAGR—-29.2%—
5-year CAGR-24.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(80.4M) USD
Year-over-year change
-55.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CAMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +66.7% is the 3rd highest of 9, against a peer median of +1.3%.
  • Net income amounts to 2193.7% of revenue for CAMP, versus a peer median of 66.4%.
CAMP Competitors
Net Income for CAMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALXOALX Oncology Holdings Inc.LTM Mar 2026$88.87M USD-31.7%-6.3%—
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$86.3M USD+66.7%—2193.7%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$78.34M USD+28.7%+2.0%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$77.27M USD-7.7%+35.7%—
ATYRaTyr Pharma, Inc.LTM Mar 2026$70.03M USD+10.4%+17.8%36859.5%
BMEABiomea Fusion, Inc.LTM Mar 2026$44.95M USD-65.1%-8.9%—
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$39.95M USD+162.9%+13.7%—
VXRTVaxart, Inc.LTM Mar 2026$37.1M USD+163.8%—14.5%
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$12.18M CAD-73.6%+21.9%66.4%
Peer median (excluding CAMP) —+1.3%+13.7%66.4%

Competitors are the stored peer set for CAMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Feb 2022
FY2022
Feb 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(27.99M)(44.19M)(49.29M)(51.79M)(80.4M)
Depreciation & Amortization22.8M878K1.68M1.7M1.64M
Deferred Income Tax00000
Stock-Based Compensation11.32M1.38M2.91M4.03M4M
Change in Working Capital1.59M373K(154K)(1.88M)13.01M
Accounts Receivables1.44M0000
Inventory5.16M0000
Accounts Payables0000(1.03M)
Other Working Capital(5.01M)373K(154K)(1.88M)14.04M
Other Non-Cash Items(11.94M)3.02M705K2.39M32.21M
Operating Cash Flow(4.22M)(38.54M)(44.16M)(45.56M)(29.55M)
Capital Expenditures(13.3M)(4.03M)(678K)(441K)(279K)
Acquisitions (Net)000036K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities5.72M0000
Investing Cash Flow(7.58M)(4.03M)(678K)(441K)(243K)
Debt Repayment—(93K)116K(824K)(208K)
Common Stock Issued000061.17M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(2.64M)100.25M185K72.49M14.93M
Financing Cash Flow(2.64M)100.16M301K71.66M75.89M
Effect of Forex Changes(965K)25.6M000
Net Change in Cash(15.4M)83.19M(44.53M)25.66M46.09M
Free Cash Flow(17.52M)(42.57M)(44.83M)(46M)(29.83M)

CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Intrinsic Alpha fair value

Locked

Current Price

$4.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.